Related Experiment Videos
Circulating antibodies in malignant melanoma patients
Dermatologica
|January 1, 1979
Summary
This study found no reliable autoantibodies against melanoma tissues in patients. However, malignant melanoma patients showed significantly higher rates of antinuclear (ANA) and cytoplasmic epidermal cell autoantibodies (A-CYT).
Area of Science:
- Immunology
- Oncology
- Dermatology
Background:
- Malignant melanoma (MM) is a significant health concern.
- Autoantibodies are implicated in various autoimmune and malignant conditions.
- Serological markers for MM are crucial for diagnosis and prognosis.
Purpose of the Study:
- To investigate the presence of specific autoantibodies in patients with malignant melanoma.
- To evaluate the diagnostic potential of autoantibodies in melanoma detection.
- To assess the correlation between autoantibodies and clinical stages of melanoma.
Main Methods:
- Indirect conventional immunofluorescent technique (IIT) and immunofluorescent complement-fixation test (ICFT) were employed.
- Sera from 46 malignant melanoma patients and 25 healthy donors were analyzed.
- Analysis included testing against autologous/homologous melanoma and non-pigmented tissues, as well as screening for various autoantibodies.
Main Results:
- No specific autoantibodies were detected against melanoma or pigmented tissues.
- A significantly increased incidence of antinuclear antibodies (ANA; 41%) and cytoplasmic epidermal cell autoantibodies (A-CYT; 71%) was observed in melanoma patients compared to controls.
- Statistical analysis confirmed the significance of ANA (p<0.05) and A-CYT (p<0.01) in melanoma patients.
Conclusions:
- Current serological tests lack reliability for detecting MM-specific autoantibodies.
- Elevated levels of ANA and A-CYT autoantibodies may serve as potential biomarkers in malignant melanoma patients.
- Further research is warranted to explore the role of these autoantibodies in melanoma pathogenesis and clinical management.